-
FibroGen’s Evrenzo Achieves Record Sales in China, Outlook for 2024 Remains Promising
•
US-based biopharmaceutical company FibroGen Inc., (NASDAQ: FGEN) has released its financial report for the second quarter of 2023, featuring record new highs for sales of the first-in-class HIF prolyl-hydroxylase inhibitor, Evrenzo (roxadustat), in China. Total net sales of Evrenzo in China, including through a joint venture with AstraZeneca, reached USD…
-
Bayer AG Reports Q2/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals
•
Germany-based multinational Bayer AG (ETR: BAYN) has released its financial report for the second quarter and first half of 2023, which indicates the group is facing difficulties due to the performance of its crop science and pharmaceutical business units. The China market, in particular, has been identified as a significant…
-
Novo Nordisk’s Wegovy Demonstrates 20% Reduction in Cardiovascular Events in SELECT Trial
•
Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) has released topline data supporting the use of its anti-obesity drug Wegovy (semaglutide). The data originates from the SELECT cardiovascular outcomes trial, which enrolled an extensive cohort of 17,604 adults suffering from obesity and established cardiovascular disease (CVD), but without diabetes. This…
-
Shanghai Health Commission Issues Regulations to Curb Unhealthy Pharmaceutical Practices
•
In alignment with the [2023] No. 75 Document by the National Health Commission, the Shanghai Municipal Health Commission has released a set of regulations aimed at correcting unhealthy practices in the field of pharmaceutical purchasing and sales and medical services within the city for the year 2023. The document mandates…
-
CanSino Biotechnology Partners with AstraZeneca for mRNA Vaccine Development and Manufacturing
•
China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced a product supply cooperation framework agreement with UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN). The agreement entails providing contract development and manufacturing services for AstraZeneca’s mRNA vaccine, with no financial details disclosed. Focus on mRNA Production Platform and Vaccine R&DThis…
-
Lynk Pharmaceuticals’ LNK01001 Shows Positive Results in Atopic Dermatitis Phase II Study
•
China-based Lynk Pharmaceuticals Co., Ltd has announced that its Phase II clinical study for LNK01001 in atopic dermatitis (AD) has yielded positive major results. The study, a randomized, double-blinded, placebo-controlled, multi-center trial, enrolled 150 patients and included high-dose and low-dose groups of LNK01001 alongside a placebo group. Study Design and…
-
BioNTech Expands Partnership with Duality Biologics for Global Rights to ADC DB-1305
•
Germany-based BioNTech SE (NASDAQ: BNTC) has entered into a cooperation expansion agreement with its existing partner, Duality Biologics (Suzhou) Co., Ltd. This new deal grants BioNTech global development, manufacturing, and commercialization rights to the antibody drug conjugate (ADC) DB-1305, excluding Greater China, which includes China mainland, Hong Kong, and Macau.…
-
Johnson & Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar
•
US pharmaceutical giant Johnson & Johnson (J&J; NYSE: JNJ) has entered into its latest settlement agreement with Fresenius Kabi and Formycon AG, granting the companies a license to launch their biosimilar version of ustekinumab, FYB202, no later than April 15, 2025. This marks the third agreement signed by J&J with…
